2. Search Result
Search Result
Results for "

osteoarthritis

" in MedChemExpress (MCE) Product Catalog:

97

Inhibitors & Agonists

1

Screening Libraries

2

Biochemical Assay Reagents

2

Peptides

6

Inhibitory Antibodies

19

Natural
Products

10

Isotope-Labeled Compounds

1

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-112545
    DDR2-IN-1
    1 Publications Verification

    		 Discoidin Domain Receptor Metabolic Disease
    DDR2-IN-1 is potent DDR2 inhibitor with an IC50 of 26 nM. DDR2-IN-1, compound 129, can be used for osteoarthritis research .
    DDR2-IN-1
  • HY-124029
    BI-4394

    MMP13-IN-3

    		 MMP Inflammation/Immunology
    BI-4394 (MMP13-IN-3) is a potent, selective, and orally active MMP-13 inhibitor (IC50=1 nM ) for the potential treatment of osteoarthritis . BI-4394 is >1000 selective over other MMPs .
    BI-4394
  • HY-155876
    NLRP3 antagonist 2

    		NOD-like Receptor (NLR) Inflammation/Immunology
    NLRP3 antagonist 2 (comopound 102) is a NLRP3 antagonist. NLRP3 antagonist 2 can be used for osteoarthritis research .
    NLRP3 antagonist 2
  • HY-P2414
    MMP-13 Substrate

    		MMP Inflammation/Immunology
    MMP-13 Substrate is a substrate of MMP-13. MMP-13 Substrate can be used for the research of osteoarthritis (OA) .
    MMP-13 Substrate
  • HY-N12648
    Anemarsaponin E1

    		Others Inflammation/Immunology
    Anemarsaponin E1 can be isolated from Guizhi-Shaoyao-Zhimu decoction (GSZD), and can be used for research of rheumatoid arthritis (RA), gout, osteoarthritis, etc .
    Anemarsaponin E1
  • HY-151524
    Cathepsin K inhibitor 3

    		Cathepsin Inflammation/Immunology
    Cathepsin K inhibitor 3 (compound 23) is a highly selective cathepsin K inhibitor with an IC50 value of 0.5 nM. Cathepsin K inhibitor 3 has a favorable pharmacokinetic profile and may be used in osteoarthritis (OA) disease studies .
    Cathepsin K inhibitor 3
  • HY-17490
    Oxaceprol
    1 Publications Verification

    N-Acetyl-L-hydroxyproline

    		 Amino Acid Derivatives Inflammation/Immunology
    Oxaceprol (N-Acetyl-L-hydroxyproline), an orally active derivative of L-proline, possesses distinct anti-inflammatory activity. Oxaceprol is usually used for the research of osteoarthritis and rheumatoid arthritis .
    Oxaceprol
  • HY-142687
    SGK1-IN-4

    		SGK Inflammation/Immunology
    SGK1-IN-4 (compound 17a) is a highly selective, orally active SGK1 inhibitor. SGK1-IN-4 can be used for osteoarthritis research .
    SGK1-IN-4
  • HY-10794
    MF498
    1 Publications Verification

    		 Prostaglandin Receptor Metabolic Disease Inflammation/Immunology Cancer
    MF498 is a selective and orally active E prostanoid Receptor 4 (EP4) antagonist with a Ki value of 0.7 nM. MF498 can be used in the research of inflammation, such as rheumatoid and osteoarthritis .
    MF498
  • HY-17361
    Etofenamate

    		COX Inflammation/Immunology
    Etofenamate, a non-steroid anti-inflammatory agent (NSAID) and a non-selective COX inhibitor, possesses analgesic, anti-rheumatic, antipyretic and anti-inflammatory properties. Etofenamate is used in the research for osteoarthritis, arthritis and other inflammatory diseases .
    Etofenamate
  • HY-17488
    Morniflumate

    UP 164

    		 Others Inflammation/Immunology
    Morniflumate (UP 164) is an orally active nonsteroidal anti-inflammatory agent. Morniflumate can be used in the study of inflammatory diseases such as osteoarthritis, painful musculoskeletal disorders and soft tissue inflammation.
    Morniflumate
  • HY-121936
    Yohimbic acid

    		Others Cardiovascular Disease Inflammation/Immunology
    Yohimbic acid is an amphoteric demethylated derivative of Yohimbine. Yohimbic acid exhibits vasodilatory action. Yohimbic acid also can be used for the research of osteoarthritis (OA) .
    Yohimbic acid
  • HY-14931
    Naproxcinod

    AZD 3582; HCT 3012; Nitronaproxen

    		 COX Inflammation/Immunology
    Naproxcinod (Nitronaproxen) is the first in class of cyclooxygenase (COX)-inhibiting nitric oxide donators (CINODs). Naproxcinod shows analgesic and anti-inflammatory effects, it can be used for the research of osteoarthritis and inflammation .
    Naproxcinod
  • HY-B0634
    Aceclofenac

    		COX Inflammation/Immunology
    Aceclofenac is an orally active nonsteroidal anti-inflammatory agent (NSAID), with analgesic and anti-inflammatory properties. Aceclofenac is used for the research of osteoarthritis, ankylosing spondylitis, rheumatoid arthritis .
    Aceclofenac
  • HY-121936A
    Yohimbic acid hydrate

    		Others Cardiovascular Disease Inflammation/Immunology
    Yohimbic acid hydrate is an amphoteric demethylated derivative of Yohimbine (HY-12715). Yohimbic acid hydrate exhibits vasodilatory action. Yohimbic acid hydrate also can be used for the research of osteoarthritis (OA) .
    Yohimbic acid hydrate
  • HY-106277A
    Fasitibant chloride hydrochloride

    MEN16132

    		 Bradykinin Receptor Metabolic Disease
    Fasitibant chloride hydrochloride (MEN16132) is a potent, selective, high affinity, and long-lasting nonpeptide bradykinin B2 (BK2) receptor antagonist. Fasitibant chloride hydrochloride has proinflammatory effects and can be used for the research of osteoarthritis and rheumatoid arthritis .
    Fasitibant chloride hydrochloride
  • HY-106277
    Fasitibant free base

    		Bradykinin Receptor Metabolic Disease
    Fasitibant (free base) is a potent, selective, high affinity, and long-lasting nonpeptide bradykinin B2 (BK2) receptor antagonist. Fasitibant (free base) has proinflammatory effects and can be used for the research of osteoarthritis and rheumatoid arthritis .
    Fasitibant free base
  • HY-P99721
    Lutikizumab

    ABT-981

    		 Interleukin Related Inflammation/Immunology
    Lutikizumab (ABT-981) is an anti-IL-1α and IL-1β dual variable domain immunoglobulin. Lutikizumab binds and inhibits IL-1α and IL-1β. Lutikizumab can be used for the research of osteoarthritis .
    Lutikizumab
  • HY-14900
    Tedalinab

    GRC-10693

    		 Cannabinoid Receptor Inflammation/Immunology
    Tedalinab (GRC-10693) is a potent, orally active, and selective cannabinoid receptor 2 (CB2) agonist. Tedalinab has >4700-fold functional selectivity for CB2 over CB1. Tedalinab has potential for neuropathic pain and osteoarthritis treatment .
    Tedalinab
  • HY-125415
    PF-4693627

    		PGE synthase Inflammation/Immunology
    PF-4693627 is a potent, selective and orally bioavailable microsomal prostaglandin E synthase-1 (mPGES-1) inhibitor (IC50=3 nM) for the treatment of inflammation caused by osteoarthritis (OA) and rheumatoid arthritis (RA) .
    PF-4693627
  • HY-14952
    Giripladib

    PLA-695

    		 Phospholipase Inflammation/Immunology Cancer
    Giripladib (PLA-695) is a indole-based inhibitor of cytosolic phospholipase A2 (cPLA2). Giripladib can be used for osteoarthritis and breast cancer research .
    Giripladib
  • HY-B2082
    Fursultiamine

    		Others Neurological Disease Inflammation/Immunology Cancer
    Fursultiamine is a vitamin B1 derivative, has anti-nociceptive and antineoplastic activity. Fursultiamine can be used for vitamin B1 deficiency, osteoarthritis (OA) and cancer research .
    Fursultiamine
  • HY-14240
    PG 116800

    PG 530742; PGE 530742; PGE 7113313

    		 MMP Inflammation/Immunology
    PG 116800 (PG 530742) is an orally avtive MMP inhibitor. PG 116800 has high affinity for MMP-2, -3, -8, -9, -13, and -14, while having substantially lower affinity for MMP-1 and -7. PG 116800 can be used for knee osteoarthritis research .
    PG 116800
  • HY-N0665
    Specnuezhenide
    1 Publications Verification

    (8E)-Nuezhenide

    		 NF-κB Wnt Inflammation/Immunology
    Specnuezhenide ((8E)-Nuezhenide) is isolated from the fruits of Ligustrum lucidum. Specnuezhenide ((8E)-Nuezhenide) can inhibit IL-1β-induced inflammation in chondrocytes via inhibition of NF-κB and wnt/β-catenin signaling. Specnuezhenide ((8E)-Nuezhenide) exerts anti-inflammatory effects in a rat model of osteoarthritis (OA) .
    Specnuezhenide
  • HY-13507
    Lumiracoxib

    COX-189

    		 COX Metabolic Disease Inflammation/Immunology Cancer
    Lumiracoxib is a potent,selective and orally active COX-2 inhibitor with a Ki value of 0.06 μM . Lumiracoxib acts as a nonselective NSAID with anti-inflammatory, analgesic and antipyretic activities. Lumiracoxib can be used for osteoarthritis and bone cancer research .
    Lumiracoxib
  • HY-142686
    SGK1-IN-3

    		SGK Inflammation/Immunology
    SGK1-IN-3 (compound 3a) is a potent and orally active inhibitor of SGK1. The serine/threonine kinase SGK1 is an activator of the β-catenin pathway and a powerful stimulator of cartilage degradation that is found to be upregulated under genomic control in diseased osteoarthritic cartilage. SGK1-IN-3 has the potential for the research of osteoarthritis .
    SGK1-IN-3
  • HY-10582
    Flurbiprofen

    dl-Flurbiprofen

    		 COX Apoptosis Inflammation/Immunology Cancer
    Flurbiprofen (dl-Flurbiprofen) is a potent, orally active nonsteroidal anti-inflammatory agent (NSAIA/NSAID), with antipyretic and analgesic activities. Flurbiprofen is commonly used for the research of inflammatory diseases, including osteoarthritis and rheumatoid arthritis. Flurbiprofen is a non-selective cyclooxygenase (COX) inhibitor that can be used for the research of colorectal cancer .
    Flurbiprofen
  • HY-107320
    Amtolmetin guacil

    		Prostaglandin Receptor COX NO Synthase Inflammation/Immunology
    Amtolmetin guacil is an effective nonsteroidal anti-Inflammatory agent with pain-relieving effects. Amtolmetin guacil inhibits prostaglandin synthesis and cyclooxygenase (COX). Amtolmetin guacil can stimulate capsaicin receptors present on the gastrointestinal wall and also releases gastroprotective nitric oxide (NO). Amtolmetin guacil can be used to research knee osteoarthritis .
    Amtolmetin guacil
  • HY-136651
    BNTA

    		Reactive Oxygen Species Inflammation/Immunology
    BNTA, a potent extracellular matrix (ECM) modulator, facilitates cartilage structural molecule synthesis on chondrocytes by activating superoxide dismutase 3 (SOD3). BNTA shows a promising potential for osteoarthritis alleviation by modulating cartilage generation .
    BNTA
  • HY-P99297
    Bedinvetmab

    ZTS-00508841

    		 Trk Receptor Inflammation/Immunology
    Bedinvetmab (ZTS-00508841) is a canine monoclonal antibody (mAb) targeting nerve growth factor (NGF). Bedinvetmab inhibits NGF interaction with tropomyosin receptor kinase A (trkA) and p75 neurotrophin receptor (p75NTR) receptors. Bedinvetmab can be used for the research of osteoarthritis pain in dogs .
    Bedinvetmab
  • HY-101588
    Gefapixant

    MK-7264; AF-219

    		 P2X Receptor Inflammation/Immunology
    Gefapixant is an orally active and potent purinergic P2X3 receptor (P2X3R) antagonist, with IC50 values of ~30 nM versus recombinant hP2X3 homotrimers and 100-250 nM at hP2X2/3 heterotrimeric receptors. Gefapixant can be used for the research of chronic cough and knee osteoarthritis .
    Gefapixant
  • HY-16268
    Kartogenin
    Maximum Cited Publications
    20 Publications Verification

    KGN

    		 TGF-beta/Smad Inflammation/Immunology
    Kartogenin (KGN) is an inducer of differentiation of human mesenchymal stem cells into chondrocytes, with an EC50 of 100 nM. Kartogenin binds filamin A, disrupts its interaction with the transcription factor core-binding factor β subunit (CBFβ), and induces chondrogenesis by regulating the CBFβ-RUNX1 transcriptional program. Kartogenin can be used for the research of osteoarthritis (OA) .
    Kartogenin
  • HY-101588A
    Gefapixant citrate

    MK-7264 citrate; AF-219 citrate

    		 P2X Receptor Inflammation/Immunology
    Gefapixant citrate is an orally active and potent purinergic P2X3 receptor (P2X3R) antagonist, with IC50 values of ~30 nM versus recombinant hP2X3 homotrimers and 100-250 nM at hP2X2/3 heterotrimeric receptors. Gefapixant citrate can be used for the research of chronic cough and knee osteoarthritis .
    Gefapixant citrate
  • HY-N1584
    Halofuginone
    5+ Cited Publications

    RU-19110

    		 DNA/RNA Synthesis TGF-beta/Smad Parasite Sodium Channel Calcium Channel Infection Cardiovascular Disease Inflammation/Immunology Cancer
    Halofuginone (RU-19110), a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a Ki of 18.3 nM . Halofuginone is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity . Halofuginone is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca 2+ channels. Halofuginone has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects .
    Halofuginone
  • HY-138761
    EP4 receptor antagonist 3

    		Prostaglandin Receptor Inflammation/Immunology Cancer
    EP4 receptor antagonist 3 is a potent EP4 receptor antagonist, example 3,extracted from patent WO2010019796 A1. EP4 receptor antagonist 3 can be used for the reseacrh of EP4 receptor-mediated diseases, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis and cancer .
    EP4 receptor antagonist 3
  • HY-N1584A
    Halofuginone hydrobromide
    5+ Cited Publications

    RU-19110 hydrobromide

    		 DNA/RNA Synthesis TGF-beta/Smad Parasite Sodium Channel Calcium Channel Infection Cardiovascular Disease Inflammation/Immunology Cancer
    Halofuginone (RU-19110) hydrobromid, a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a Ki of 18.3 nM . Halofuginone hydrobromid is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity . Halofuginone hydrobromid is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca 2+ channels. Halofuginone hydrobromid has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects .
    Halofuginone hydrobromide
  • HY-N1584B
    Halofuginone hydrochloride

    RU-19110 hydrochloride

    		 Calcium Channel DNA/RNA Synthesis Parasite Sodium Channel TGF-beta/Smad Infection Cardiovascular Disease Inflammation/Immunology Cancer
    Halofuginone (RU-19110) hydrobromid, a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a Ki of 18.3 nM. Halofuginone hydrobromid is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity. Halofuginone hydrobromid is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca 2+ channels. Halofuginone hydrobromid has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects .
    Halofuginone hydrochloride
  • HY-108519
    AS1892802

    		ROCK Neurological Disease
    AS1892802 is a potent, orally active, and highly selective inhibitor of ROCK. The onset of antinociceptive effect of AS1892802 is as fast as those of Tramadol and Diclofenac. AS1892802 did not induce gastric irritation or abnormal behavior. AS1892802 is an attractive analgesic profile for the research of severe osteoarthritis pain .
    AS1892802
  • HY-B0617
    S-Adenosyl-L-methionine

    S-Adenosyl methionine; Ademetionine; AdoMet

    		 Endogenous Metabolite Apoptosis Neurological Disease Inflammation/Immunology Cancer
    S-Adenosyl-L-methionine (S-Adenosyl methionine) is an orally active methyl group donor. S-Adenosyl-L-methionine is a dietary supplement with potent antidepressant effects. S-Adenosyl-L-methionine also has anti‑proliferative, pro‑apoptotic and anti‑metastatic roles in cancers. S-Adenosyl-L-methionine has the potential for, cancer, liver disease and osteoarthritis research .
    S-Adenosyl-L-methionine
  • HY-N0866
    20-Deoxyingenol
    1 Publications Verification

    		 Autophagy Inflammation/Immunology
    20-Deoxyingenol, a diterpene, is isolated from the roots of Euphorbia kansui. 20-Deoxyingenol can promote autophagy and lysosomal biogenesis by promoting the nuclear translocation of transcription factor EB (TFEB) in vitro. 20-Deoxyingenol can be used for the research of osteoarthritis (OA) .
    20-Deoxyingenol
  • HY-19676
    Pralnacasan

    VX-740; HMR 3480

    		 Caspase Inflammation/Immunology
    Pralnacasan (VX-740) is a potent, selective, non-peptide and orally active interleukin-1β converting enzyme (ICE, caspase 1) inhibitor with a Ki of 1.4 nM. Pralnacasan inhibits proinflammatory cytokines IL-18, IL-1β , and IFN-γ. Pralnacasan has the potential for osteoarthritis and rheumatoid arthritis treatment .
    Pralnacasan
  • HY-108672
    NF157

    		P2Y Receptor Inflammation/Immunology
    NF157 is a highly selective nanomolar P2Y11 antagonist with a pKi of 7.35. The IC50s are 463 nM, 1811 µM, 170 µM for P2Y11 (Ki=44.3 nM), P2Y1 (Ki=187 µM), P2Y2 (Ki=28.9 µM), respectively . NF157, significantly reduces expression of metalloproteinase (MMP)-3, MMP-13, can be used in the treatment of osteoarthritis (OA) .
    NF157
  • HY-17474
    Parecoxib
    1 Publications Verification

    SC 69124

    		 COX Inflammation/Immunology Cancer
    Parecoxib (SC 69124) is a highly selective and orally active COX-2 inhibitor, the proagent of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis. Parecoxib can be used for the relief of acute postoperative pain and symptoms of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis in vivo.
    Parecoxib
  • HY-17474A
    Parecoxib Sodium
    1 Publications Verification

    SC 69124A

    		 COX Inflammation/Immunology Cancer
    Parecoxib Sodium (SC 69124A) is a highly selective and orally active COX-2 inhibitor, the proagent of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis. Parecoxib Sodium can be used for the relief of acute postoperative pain and symptoms of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis in vivo.
    Parecoxib Sodium
  • HY-120793
    CMC2.24

    TRB-N0224

    		 Ras Apoptosis MMP Inflammation/Immunology Cancer
    CMC2.24 (TRB-N0224), an orally active tricarbonylmethane agent, is effective against pancreatic tumor in mice by inhibiting Ras activation and its downstream effector ERK1/2 pathway. CMC2.24 is also a potent inhibitor of zinc-dependent MMPs with IC50s ranging from 2.0-69 μM. CMC2.24 alleviates osteoarthritis progression by restoring cartilage homeostasis and inhibiting chondrocyte apoptosis via the NF-κB/HIF-2α axis .
    CMC2.24
  • HY-N0283
    Diacerein
    1 Publications Verification

    Diacerhein; Diacetylrhein

    		 Interleukin Related Calcium Channel Inflammation/Immunology
    Diacerein (Diacerhein), an orally active anthraquinone, reduces production of IL-1 converting enzyme then inhibits the activation of IL-1β by related downstream signaling. Diacerein is an anti-inflammatory and anti-rheumatic drug. Diacerein can relieve bronchospasm and control airway inflammation in asthmatic mice. Diacerein has the potential for slow acting drug in osteoarthritis (SYSADOA) research .
    Diacerein
  • HY-W017770
    S-Adenosyl-L-methionine disulfate tosylate
    5+ Cited Publications

    Ademetionine disulfate tosylate; S-Adenosyl methionine disulfate tosylate; AdoMet disulfate tosylate

    		 Endogenous Metabolite Apoptosis Neurological Disease Cancer
    S-Adenosyl-L-methionine disulfate tosylate is the disulfate tosylate form of S-Adenosyl-L-methionine (HY-B0617). S-Adenosyl-L-methionine is an orally active methyl group donor. S-Adenosyl-L-methionine is a dietary supplement with potent antidepressant effects. S-Adenosyl-L-methionine also has anti‑proliferative, pro‑apoptotic and anti‑metastatic roles in cancers. S-Adenosyl-L-methionine has the potential for, cancer, liver disease and osteoarthritis research .
    S-Adenosyl-L-methionine disulfate tosylate
  • HY-153335
    Enpp-1-IN-16

    		Phosphodiesterase (PDE) Infection Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    Enpp-1-IN-16 (compound 54) is an ENPP1 inhibitor. Enpp-1-IN-16 has the potential to study cancer, especially in cases of high ENPP1 expression or elevated cytoplasmic DNA levels. Enpp-1-IN-16 can also be used in other diseases mediated by ENPP1, such as bacterial or viral infections, insulin resistance and type II diabetes, chondrocalcinosis and osteoarthritis, calcium pyrophosphate deposition disorder (CPPD), low Phosphatase disease and soft tissue calcification disorders .
    Enpp-1-IN-16
  • HY-149377
    MMP13-IN-4

    		MMP Metabolic Disease
    MMP13-IN-4 (compound 13) is a potent and selective inhibitor of MMP-13 (IC50=14.6 μM)，involved in osteoarthritis (OA) .
    MMP13-IN-4
  • HY-19771
    amyloid P-IN-1

    		Amyloid-β Cancer
    amyloid P-IN-1 is used in the research of diseases or disorders wherein depletion of serum amyloid P component (SAP), including amyloidosis, Alzheimer's disease, type 2 diabetes mellitus and osteoarthritis.
    amyloid P-IN-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: